Literature DB >> 22093106

Use of a gentamicin-impregnated collagen sheet (Collatamp(®) ) following implantation of a sacral nerve stimulator for faecal incontinence.

J A D Simpson1, J Peacock, C Maxwell-Armstrong.   

Abstract

AIM: Gentamicin-impregnated collagen (Collatamp(®) ) is well described for the prevention of infection in surgery. This technical note describes its intraoperative use as a prophylactic measure to prevent infection following implantation of a sacral nerve stimulator for faecal incontinence.
METHOD: Following implantation of the Interstim II Neurostimulator (Medtronic Neuromodulation, 710 Medtronic Parkway, Minneapolis, USA) in a subcutaneous pocket overlying the gluteal muscle, a single sheet of 10cm × 10cm gentamicin-impregnated collagen is placed within the wound covering the implant. The subcutaneous tissue and skin are then closed in separate layers.
RESULTS: To date eight patients [median age 46.5 (30-59) years] have received prophylactic cover with gentamicin-impregnated collagen following permanent sacral nerve stimulator implantation. At a median interval of 89.5 (51-128) days, none of these patients developed a wound infection at the site of the neurostimulator implant.
CONCLUSION: Gentamicin-impregnated collagen (Collatamp(®) ) used in the implantation of a sacral nerve stimulator may be a useful addition to the technique.
© 2011 The Authors. Colorectal Disease © 2011 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22093106     DOI: 10.1111/j.1463-1318.2011.02886.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  2 in total

Review 1.  Sacral Neuromodulation Implant Infection: Risk Factors and Prevention.

Authors:  Calvin Lee; Javier Pizarro-Berdichevsky; Marisa M Clifton; Sandip P Vasavada
Journal:  Curr Urol Rep       Date:  2017-02       Impact factor: 3.092

2.  Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration.

Authors:  Klaus Bielefeldt
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.